In Q2 2026, Harrow, Inc. reported ongoing investment in its branded ophthalmic pharmaceuticals portfolio with new biosimilar launches planned and a deepening pipeline including the MELT-300 sublingual sedation therapy. The company’s business model mixes sales from FDA-approved branded products with revenue from pharmaceutical compounding services aimed at eyecare professionals. Harrow's competitive position relies on its broad product range and late-stage assets but faces headwinds from intensified pricing and reimbursement pressures, regulatory risks, and legal contingencies. Growth drivers include aging demographics, innovative product development, and international licensing agreements. Monitoring commercial ramp of biosimilars BYOOVIZ and OPUVIZ, along with evolving reimbursement policies, will be crucial indicators of Harrow’s trajectory.